Köpekbalığı Kıkırdağı
Özet
Kanser hastalarının %80'inin ek veya alternatif tedavileri araştırdıkları, geleneksel ve alternatif tıp kullanım sıklığının giderek artığı ve bunların %6-%25'inin köpek balığı kıkırdağı kullandıkları ileri sürülmüştür. Köpek balığı kıkırdağının kanser gelişimini durdurduğunu veya yavaşlattığı iddialarına karşı bilim insanları, laboratuvar ve hayvan çalışmaları ile köpek balığı kıkırdak ürünlerinin, bağışıklık sistemini kansere karşı daha aktif hale getirip getirmediğini, kanser hücrelerini öldürüp öldürmediğini ve vücudun tümörün büyümesi için ihtiyaç duyduğu yeni kan damarlarını oluşumunu engelleyip engellemediğini araştırmıştır. Bu yazımızda bilimsel çalışmalar araştırılmış ve köpek balığı kıkırdağının, kanser tedavisindeki yeri tartışılmıştır. Bilimsel kanıtlar köpek balığı kıkırdağı takviyelerinin insanlarda kanser için etkili bir tedavi olduğu iddialarını desteklememektedir. Gelecekte güvenilir sonuçlar elde etmek için alternatif tedavi de kullanılan ya da kullanılabilecek ilaç adaylarını, sıkı bir şekilde kontrol edilen, randomize ve çift kör standart klinik araştırmalara tabi tutulması gerektiğidir.
It has been suggested that 80% of cancer patients seek additional or alternative therapies, and that the use of traditional and alternative medicine is increasing, with 6%-25% of these using shark cartilage.
In response to claims that shark cartilage stops or slows the development of cancer, scientists have used laboratory and animal studies to investigate whether shark cartilage products make the immune system more active against cancer, kill cancer cells and prevent the body from forming new blood vessels needed for tumor growth.In this article, we review the scientific studies and discuss the role of shark cartilage in cancer treatment.
Scientific evidence does not support claims that shark cartilage supplements are an effective treatment for cancer in humans. To ensure reliable results in the future, drug candidates that are or may be used in alternative treatment should be subjected to strictly controlled, randomized and double-blind standardized clinical trials.
Referanslar
Bao Y, Kong X, Yang L, et al. Complementary and alternative medicine for cancer pain: an overview of systematic reviews. Evid Based Complement Alternat Med 2014;2014:170396. https://doi. org/10.1155/2014/170396
Üstündağ S, Demir Zencirci A. Complementary and alternative medicine use among cancer patients and determination of affecting factors: a questionnaire study. Holist Nurs Pract 2015;29:357-369. https://doi. org/10.1097/HNP.0000000000000113
Metin Deniz Karakoç, Onkoloji hastalarının tamamlayıcı ve alternatif tedavi yöntemlerini kullanma durumları The status of oncology patients about using complementary and alternative treatment methods Pamukkale Tıp Dergisi Pamukkale,Medical,Journal,doi:https://dx.doi.org/10.31362/patd.640488
White JD. Complementary and alternative medicine research: a National Cancer Institute perspective. Semin Oncol 2002;29:546-551. https://doi.org/10.1053/ sonc.2002.50003
Murphy, C., Hotchkiss, S., Worthington, J. et al. The potential of seaweed as a source of drugs for use in cancer chemotherapy. J Appl Phycol 26, 2211–2264 (2014). https://doi.org/10.1007/s10811-014-0245-2
Ernst E, Cassileth BR. How useful are unconventional cancer treatments? Eur J Cancer. Oct 1999;35(11):1608-1613.
Kav S, Hanoğlu Z, Algier L. Türkiye’de kanserli hastalarda tamamlayıcı ve alternatif tedavi yöntemlerinin kullanımı: literatür taraması. UHOD 2008;18:32-38.
Özçelik H, Fadıloğlu Ç. Kanser hastalarının tamamlayıcı ve alternatif tedavi kullanım nedenleri. Türk Onkoloji Dergisi 2009;24:48-52.
Ahmet Emin Erbaycu, Mehmet Gülpek, Fevziye Tuksavul, et al. Akciğer Kanserinde Çeşitli Bitkisel ve Diğer Karışımların Kullanımına Sosyo-Demografik ve Tümöre Bağlı Faktörlerin Etkisi (Akciğer Kanserinde Tamamlayıcı Tedavi Kullanımı), İzmir Dr. Suat Seren Göğüs Hastanesi ve Cerrahisi, Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Kliniği, İzmir, Türkiye
Herman, P.M.; Craig, B.M.; Caspi, O. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. BMC Complement Altern. Med. 2005
Paul Posadzki,Shark cartilage for cancer patients: a mini systematic review Focus on Alternative and Complementary Therapies Volume (2011).16(3) 657-659.204207
Finkelstein, J. B. Sharks Do Get Cancer: Few Surprises in Cartilage Research. JNCI: Journal of the National Cancer Institute,(2005).97(21), 1562–1563. doi:10.1093/jnci/dji392
Jamie L. Gerlach, Brittany N. Stevens, Michael M. Garner, et al. "Prımary Hepatıc Neoplasıa In Three Adult BambooSharks(ChıloscyllıumPlagıosum And Chıloscyllıum Punctatum) In An Aquarıum Populatıon," Journal of Zoo and Wildlife Medicine 54(4), 865-872, (9 January 2024). https://doi.org/10.1638/2023-0018
Holt S: Shark cartilage and nutriceutical update. Altern Complement Ther 1 (6): 414-16, 1995
Murphy, C., Hotchkiss, S., Worthington, J. et al. The potential of seaweed as a source of drugs for use in cancer chemotherapy. J Appl Phycol 26, 2211–2264 (2014). https://doi.org/10.1007/s10811-014-0245-2
PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Cartilage (Bovine and Shark). Bethesda, MD: National Cancer Institute. Updated <23/08/2018>.Availableat: https://www.cancer.gov/cancer/treatment/cam/hp/cartilage-pdq.Accessed <10/01/2024>. [PMID: 26389205]
http://www.cancer.org/treatment/treatmentsandsideeffects/complementar,yandalternativemedicine/pharmacologicalandbiologicaltreatment/shark- cartilage
Oikawa T, Ashino-Fuse H, Shimamura M, et al. A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory adhesion and induces reorganization of focal adhesions in cultured endothelial cells. J activities toward tumor and embryonic angiogenesis. Cancer Lett. Jun 15 1990;51(3):181-186.
Loprinzi, C.L., Levitt, R., Barton, D.L., et al. Evaluation of shark cartilage in patients with advanced cancer. Cancer, (2005), 104: 176-182. https://doi.org/10.1002/cncr.21107
Cho J, Kim Y. Sharks: a potential source of antiangiogenic factors and tumor treatments. Marine Biotechnology (NY). 2002,4(6):521-5.
Li CY, Shan S, Huang Q, et al.: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2): 143-
Maria Vadalà, Carmen Laurino, Lucia Palmieri, et al. Shark derivatives (Alkylglycerols, Squalene, Cartilage) as putative nutraceuticals in oncology; June 2017 European Journal of Oncology 22(1):5-20
Milner M: A guide to the use of shark cartilage in the treatment of arthritis and other inflammatory joint diseases. American Chiropractor 21 (4): 40-2, 1999.
Himmel PB, Seligman TM: Treatment of systemic sclerosis with shark cartilage extract. Journal of Orthomolecular Medicine 14 (2): 73-7, 1999. Also available online.Last accessed April 8, 2016.
Pettit GR, Ode RH. Antineoplastic agents: Isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark. J Pharm Sci. 1976; 66: 757–758.
Gawler I. You can conquer cancer. Melbourne: Hill of Content Publishing, 1984.
Lee A, Langer R. Shark cartilage contains inhibitors of tumor antigenesis. Science. 1983; 221: 1185–1187.
Cataldi JM, Osborne DL. Effects of shark cartilage on mammary tumor neovascularization in vivo and cell proliferation in vitro [Abstract]. FASEB J. 1995; 9: A135.
González RP, Leyva A, Moraes MO. Shark cartilage as source of antiangiogenic compounds: from basic to clinical research. Biol Pharm Bull. 2001 Oct;24(10):1097-101. doi: 10.1248/bpb.24.1097. PMID: 11642310.
Hillman JD, Peng AT, Gilliam AC et al. Treatment of Kaposi's sarcoma in a human herpesvirus 8-seropositive, human immunodeficiency virus-seronegative man by oral administration of shark cartilage. Arch Dermatol. September 2001;137(9):1149-1152.
Dupont E, Savard PE, Jourdain C, et al: Antiangiogenic properties of a novel shark cartilage extract: potential role in psoriasis treatment. JCutan Med Surg 2 (3): 146-52, 1998.
Sauder DN, Dekoven J, Champagne P et al. Neovastat (AE-941), an angiogenesis inhibitor: Independent randomized phase I/II clinical trial results in plaque psoriasis. J Am Acad Dermatol. October 2002;47(4):535-541.
Cataldi JM, Osborne DL. Effects of shark cartilage on mammary tumor neovascularization in vivo and cell proliferation in vitro [Abstract]. FASEB J. 1995; 9: A135.
Latreille J, Batist G, Laberge F, et al.: Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 4 (4): 231-6, 2003.
Sheu JR, Fu CC, Tsai ML, et al: Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 18 (6A): 4435 -41, 1998 Nov-Dec.
Davis PF, He Y, Furneaux RH, et al: Inhibition of angiogenesis by oral preparation of powdered shark cartilage in a rat model. Microvasc Res 54 (2): 178-82, 1997.
Morris GM, Coderre JA, Micca PL, et al: Boron neutron capture of rat 9L gliosarcoma: evaluation of the effects of shark cartilage. Br J Radiol 73 (868): 429-34, 2000.
Horsman MR, Alsner J, Overgaard J: Effect of shark cartilage extracts on the surface of SCCVII carcinoma growth and metastatic lysis. Acta Oncol 37 (5): 441-5, 1998.
Barber R, Delahunt B, Grebe SK, Davis PF, Thornton A, Slim GC. (2001).Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. Anticancer Res.;21(2A):1065-9
Mıller, D R Et Al. “Phase I/Iı Trıal Of The Safety And Effıcacy Of Shark Cartılage In The Treatment Of Advanced Cancer.” Journal Of Clınıcal Oncology : Offıcıal Journal Of The Amerıcan Socıety Of Clınıcal Oncology Vol. 16,11 (1998): 3649-55. Doı:10.1200/Jco.1998.16.11.3649
Batist G, Patenaude F, Champagne P et al. Neovastat (AE-941) in patients with refractory renal cell carcinoma: report of a phase II study with two dose levels. Ann Oncol. August 2002;13(8):1259-1263.
Bukowski RM: AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 12 (8): 1403-11, 2003.
Weber MH, Lee J, Orr FW. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol. 2002 Feb;20(2):299303. PMID: 11788892.
Dupont E, Falardeau P, Mousa SA, et al: Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19 (2): 145-53, 2002.
Gingras D, Renaud A, Mousseau N, et al.: Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 21 (1A): 145-55,2001 Jan-Feb.
Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.
Gingras D, Batist G, Béliveau R: AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1 (3): 341-7, 2001.
Gingras D, Boivin D, Deckers C, et al.: Neovastat--a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14 (2): 91-6, 2003.
Lu C, Lee JJ, Komaki R et al.( 2010).Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst; 102: 859-65.
Ryoo JJ, Cole CE, Anderson KC: Novel therapies for multiple myeloma. Blood Rev 16 (3): 167-74, 2002.
Kim M. Mercury, cadmium and arsenic contents of calcium dietary supplements. Food Addit Contam. 2004;21(8):763-767.15370826
Mondo K, Broc Glover W, Murch SJ, et al. Environmental neurotoxins β-N-methylamino-L-alanine (BMAA) and mercury in shark cartilage dietary supplements. Food Chem Toxicol. 2014;70:26-32.24755394
Ashar B, Vargo E. Shark cartilage-induced hepatitis. Ann Intern Med. Nov 1 1996;125(9):780-781.
Mundy GR, Mazzaferri EL (1994) Evaluation and treatment of hypercalcemia. Hosp Pract 29:79–86
Lagman, R., Walsh, D. Dangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia. Support Care Cancer 11, 232–235 (2003). https://doi.org/10.1007/s00520-002-0428
Sparreboom, A.; Cox, M.C.; Acharya, M.R.; et al. Herbal remedies in the united states: Potential adverse interactions with anticancer agents. J. Clin. Oncol. 2004, 22, 2489–2503.
Satia, J.A.; Littman, A.; Slatore, C.G.; et al. Long-term use of beta-carotene, retinol, lycopene, and lutein supplements and lung cancer risk: Results from the vitamins and lifestyle (vital) study. Am. J. Epidemiol. 2009, 169, 815–828.
Williams GR, Deal AM, Lund JL, et al. Patient-reported comorbidity and survival in older adults with cancer. Oncologist 2018;23:433-439. https://doi.org/10.1634/ theoncologist.2017-0404
Dutkowska AE, Antczak A. Comorbidities in lung cancer. Pneumonol Alergol Pol 2016;84:186-192. https://doi.org/10.5603/PiAP.2016.0022
Smith PJ, Clavarino A, Long J, et al. Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks? Asia Pac J Clin Oncol 2014;10:110. https://doi.org/10.1111/ajco.12115
Federal Trade Commission. Cure.all Operation Nets Shark Cartilage Supporters: Shark Cartilage and Skin Cream
Weiger WA, Smith M, Boon H, et al. Counseling patients seeking complementary and alternative medical treatments for cancer. Ann Intern Med.2002;137:889-903.
Üstündağ S, Demir Zencirci A. Complementary and alternative medicine use among cancer patients and determination of affecting factors: a questionnaire study. Holist Nurs Pract 2015;29:357-369. https://doi. org/10.1097/HNP.0000000000000113
Metin Deniz Karakoç, Onkoloji hastalarının tamamlayıcı ve alternatif tedavi yöntemlerini kullanma durumları The status of oncology patients about using complementary and alternative treatment methods Pamukkale Tıp Dergisi Pamukkale,Medical,Journal,doi:https://dx.doi.org/10.31362/patd.640488
White JD. Complementary and alternative medicine research: a National Cancer Institute perspective. Semin Oncol 2002;29:546-551. https://doi.org/10.1053/ sonc.2002.50003
Murphy, C., Hotchkiss, S., Worthington, J. et al. The potential of seaweed as a source of drugs for use in cancer chemotherapy. J Appl Phycol 26, 2211–2264 (2014). https://doi.org/10.1007/s10811-014-0245-2
Ernst E, Cassileth BR. How useful are unconventional cancer treatments? Eur J Cancer. Oct 1999;35(11):1608-1613.
Kav S, Hanoğlu Z, Algier L. Türkiye’de kanserli hastalarda tamamlayıcı ve alternatif tedavi yöntemlerinin kullanımı: literatür taraması. UHOD 2008;18:32-38.
Özçelik H, Fadıloğlu Ç. Kanser hastalarının tamamlayıcı ve alternatif tedavi kullanım nedenleri. Türk Onkoloji Dergisi 2009;24:48-52.
Ahmet Emin Erbaycu, Mehmet Gülpek, Fevziye Tuksavul, et al. Akciğer Kanserinde Çeşitli Bitkisel ve Diğer Karışımların Kullanımına Sosyo-Demografik ve Tümöre Bağlı Faktörlerin Etkisi (Akciğer Kanserinde Tamamlayıcı Tedavi Kullanımı), İzmir Dr. Suat Seren Göğüs Hastanesi ve Cerrahisi, Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Kliniği, İzmir, Türkiye
Herman, P.M.; Craig, B.M.; Caspi, O. Is complementary and alternative medicine (CAM) cost-effective? A systematic review. BMC Complement Altern. Med. 2005
Paul Posadzki,Shark cartilage for cancer patients: a mini systematic review Focus on Alternative and Complementary Therapies Volume (2011).16(3) 657-659.204207
Finkelstein, J. B. Sharks Do Get Cancer: Few Surprises in Cartilage Research. JNCI: Journal of the National Cancer Institute,(2005).97(21), 1562–1563. doi:10.1093/jnci/dji392
Jamie L. Gerlach, Brittany N. Stevens, Michael M. Garner, et al. "Prımary Hepatıc Neoplasıa In Three Adult BambooSharks(ChıloscyllıumPlagıosum And Chıloscyllıum Punctatum) In An Aquarıum Populatıon," Journal of Zoo and Wildlife Medicine 54(4), 865-872, (9 January 2024). https://doi.org/10.1638/2023-0018
Holt S: Shark cartilage and nutriceutical update. Altern Complement Ther 1 (6): 414-16, 1995
Murphy, C., Hotchkiss, S., Worthington, J. et al. The potential of seaweed as a source of drugs for use in cancer chemotherapy. J Appl Phycol 26, 2211–2264 (2014). https://doi.org/10.1007/s10811-014-0245-2
PDQ® Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Cartilage (Bovine and Shark). Bethesda, MD: National Cancer Institute. Updated <23/08/2018>.Availableat: https://www.cancer.gov/cancer/treatment/cam/hp/cartilage-pdq.Accessed <10/01/2024>. [PMID: 26389205]
http://www.cancer.org/treatment/treatmentsandsideeffects/complementar,yandalternativemedicine/pharmacologicalandbiologicaltreatment/shark- cartilage
Oikawa T, Ashino-Fuse H, Shimamura M, et al. A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory adhesion and induces reorganization of focal adhesions in cultured endothelial cells. J activities toward tumor and embryonic angiogenesis. Cancer Lett. Jun 15 1990;51(3):181-186.
Loprinzi, C.L., Levitt, R., Barton, D.L., et al. Evaluation of shark cartilage in patients with advanced cancer. Cancer, (2005), 104: 176-182. https://doi.org/10.1002/cncr.21107
Cho J, Kim Y. Sharks: a potential source of antiangiogenic factors and tumor treatments. Marine Biotechnology (NY). 2002,4(6):521-5.
Li CY, Shan S, Huang Q, et al.: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2): 143-
Maria Vadalà, Carmen Laurino, Lucia Palmieri, et al. Shark derivatives (Alkylglycerols, Squalene, Cartilage) as putative nutraceuticals in oncology; June 2017 European Journal of Oncology 22(1):5-20
Milner M: A guide to the use of shark cartilage in the treatment of arthritis and other inflammatory joint diseases. American Chiropractor 21 (4): 40-2, 1999.
Himmel PB, Seligman TM: Treatment of systemic sclerosis with shark cartilage extract. Journal of Orthomolecular Medicine 14 (2): 73-7, 1999. Also available online.Last accessed April 8, 2016.
Pettit GR, Ode RH. Antineoplastic agents: Isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark. J Pharm Sci. 1976; 66: 757–758.
Gawler I. You can conquer cancer. Melbourne: Hill of Content Publishing, 1984.
Lee A, Langer R. Shark cartilage contains inhibitors of tumor antigenesis. Science. 1983; 221: 1185–1187.
Cataldi JM, Osborne DL. Effects of shark cartilage on mammary tumor neovascularization in vivo and cell proliferation in vitro [Abstract]. FASEB J. 1995; 9: A135.
González RP, Leyva A, Moraes MO. Shark cartilage as source of antiangiogenic compounds: from basic to clinical research. Biol Pharm Bull. 2001 Oct;24(10):1097-101. doi: 10.1248/bpb.24.1097. PMID: 11642310.
Hillman JD, Peng AT, Gilliam AC et al. Treatment of Kaposi's sarcoma in a human herpesvirus 8-seropositive, human immunodeficiency virus-seronegative man by oral administration of shark cartilage. Arch Dermatol. September 2001;137(9):1149-1152.
Dupont E, Savard PE, Jourdain C, et al: Antiangiogenic properties of a novel shark cartilage extract: potential role in psoriasis treatment. JCutan Med Surg 2 (3): 146-52, 1998.
Sauder DN, Dekoven J, Champagne P et al. Neovastat (AE-941), an angiogenesis inhibitor: Independent randomized phase I/II clinical trial results in plaque psoriasis. J Am Acad Dermatol. October 2002;47(4):535-541.
Cataldi JM, Osborne DL. Effects of shark cartilage on mammary tumor neovascularization in vivo and cell proliferation in vitro [Abstract]. FASEB J. 1995; 9: A135.
Latreille J, Batist G, Laberge F, et al.: Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 4 (4): 231-6, 2003.
Sheu JR, Fu CC, Tsai ML, et al: Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 18 (6A): 4435 -41, 1998 Nov-Dec.
Davis PF, He Y, Furneaux RH, et al: Inhibition of angiogenesis by oral preparation of powdered shark cartilage in a rat model. Microvasc Res 54 (2): 178-82, 1997.
Morris GM, Coderre JA, Micca PL, et al: Boron neutron capture of rat 9L gliosarcoma: evaluation of the effects of shark cartilage. Br J Radiol 73 (868): 429-34, 2000.
Horsman MR, Alsner J, Overgaard J: Effect of shark cartilage extracts on the surface of SCCVII carcinoma growth and metastatic lysis. Acta Oncol 37 (5): 441-5, 1998.
Barber R, Delahunt B, Grebe SK, Davis PF, Thornton A, Slim GC. (2001).Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. Anticancer Res.;21(2A):1065-9
Mıller, D R Et Al. “Phase I/Iı Trıal Of The Safety And Effıcacy Of Shark Cartılage In The Treatment Of Advanced Cancer.” Journal Of Clınıcal Oncology : Offıcıal Journal Of The Amerıcan Socıety Of Clınıcal Oncology Vol. 16,11 (1998): 3649-55. Doı:10.1200/Jco.1998.16.11.3649
Batist G, Patenaude F, Champagne P et al. Neovastat (AE-941) in patients with refractory renal cell carcinoma: report of a phase II study with two dose levels. Ann Oncol. August 2002;13(8):1259-1263.
Bukowski RM: AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 12 (8): 1403-11, 2003.
Weber MH, Lee J, Orr FW. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol. 2002 Feb;20(2):299303. PMID: 11788892.
Dupont E, Falardeau P, Mousa SA, et al: Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19 (2): 145-53, 2002.
Gingras D, Renaud A, Mousseau N, et al.: Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 21 (1A): 145-55,2001 Jan-Feb.
Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.
Gingras D, Batist G, Béliveau R: AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1 (3): 341-7, 2001.
Gingras D, Boivin D, Deckers C, et al.: Neovastat--a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14 (2): 91-6, 2003.
Lu C, Lee JJ, Komaki R et al.( 2010).Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst; 102: 859-65.
Ryoo JJ, Cole CE, Anderson KC: Novel therapies for multiple myeloma. Blood Rev 16 (3): 167-74, 2002.
Kim M. Mercury, cadmium and arsenic contents of calcium dietary supplements. Food Addit Contam. 2004;21(8):763-767.15370826
Mondo K, Broc Glover W, Murch SJ, et al. Environmental neurotoxins β-N-methylamino-L-alanine (BMAA) and mercury in shark cartilage dietary supplements. Food Chem Toxicol. 2014;70:26-32.24755394
Ashar B, Vargo E. Shark cartilage-induced hepatitis. Ann Intern Med. Nov 1 1996;125(9):780-781.
Mundy GR, Mazzaferri EL (1994) Evaluation and treatment of hypercalcemia. Hosp Pract 29:79–86
Lagman, R., Walsh, D. Dangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia. Support Care Cancer 11, 232–235 (2003). https://doi.org/10.1007/s00520-002-0428
Sparreboom, A.; Cox, M.C.; Acharya, M.R.; et al. Herbal remedies in the united states: Potential adverse interactions with anticancer agents. J. Clin. Oncol. 2004, 22, 2489–2503.
Satia, J.A.; Littman, A.; Slatore, C.G.; et al. Long-term use of beta-carotene, retinol, lycopene, and lutein supplements and lung cancer risk: Results from the vitamins and lifestyle (vital) study. Am. J. Epidemiol. 2009, 169, 815–828.
Williams GR, Deal AM, Lund JL, et al. Patient-reported comorbidity and survival in older adults with cancer. Oncologist 2018;23:433-439. https://doi.org/10.1634/ theoncologist.2017-0404
Dutkowska AE, Antczak A. Comorbidities in lung cancer. Pneumonol Alergol Pol 2016;84:186-192. https://doi.org/10.5603/PiAP.2016.0022
Smith PJ, Clavarino A, Long J, et al. Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks? Asia Pac J Clin Oncol 2014;10:110. https://doi.org/10.1111/ajco.12115
Federal Trade Commission. Cure.all Operation Nets Shark Cartilage Supporters: Shark Cartilage and Skin Cream
Weiger WA, Smith M, Boon H, et al. Counseling patients seeking complementary and alternative medical treatments for cancer. Ann Intern Med.2002;137:889-903.
Sayfalar
303-312
Yayınlanan
11 Mart 2024
Telif Hakkı (c) 2024 Akademisyen Yayınevi Kitap Portalı
Lisans
LisansNasıl Atıf Yapılır
1.
Genç Ö. Köpekbalığı Kıkırdağı. Içinde: Sakin A, editör. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim [Internet]. Türkiye: Akademisyen Yayınevi Kitap DOI Portalı; 2024 [a.yer 13 Temmuz 2026]. ss. 303-12. Erişim adresi: https://omp35.books.akademisyen.net/index.php/akya/catalog/book/2380/chapter/13932
